참고문헌
- Husband J, MacVicar D. Assessment of response totreatment and dectection of relapse. In: HusbandJES, Rezenek RH, editors. Imaging in oncology.Oxford: Isis Medical Media Ltd.: 1998. P.899-924.
- Brock CS, Young H, O'Reilly SM, Matthews J,Osman S, Evans H, et al. Early evaluation of tumourmetabolic response using[18F]fluorodeoxyglucose andpositron emission tomography; a pilot studyfollowing the phase I1 chemotherapy schedule fortemozolomide in recurrent high -rade gliomas. Br JCancer 2000;8:608-15.
- Ogawa T, Uemura K, Shishido F, Yamaguchi T,Murakami M, Inugami A, et al. Changes ofcerebral blood flow, and oxygen and glucosemetabolism following radiochemotherapy of glioma;a PET study. J Comp Assist Tomogr 1988;12:290-7.
- Haberkorn U. Strauss LG. Dimitrakopoulou A.Seiffert E. Oberdorfer F. Ziegler S. et al.Fluordeoxyglucose imaging of advanced head andneck cancer after chemotherapy. J Nucl Med1993;34:12-7.
- Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T,Jerusalem G, et al. Oncological applications ofpositron emission tomography with fluorine-18fluorodexy-glucose. Eur J Nucl Med 1996;23:1641-74.
- Weber WA, Ott K, Becker K, DitHer HJ,Helmberger H, Avril NE, et al. Prediction ofresponse to preoperative chemotherapy inadenocarcinomas of the esophagogastric junction bymetabolic imaging. J Clin Oneal 2001;19:3058-65
- Brock CS, Meikle SR, Price P. Dose fluorine-18fluorodeoxy-glucose metabolic imaging of tumoursbenefit oncology? Eur J Nucl Med 1997;24;691-705.
- Oosterom AT, Judson I, Verweij J, Stroobants S,Paola ED, Dimitrijevic S, et al. Safety and efficacyof imatinb(STI571) in metastatic gastrointestinalstromal tumors; a phase I study. Lancet 2001;358:1421-3.
- Dehdadashti F, Flanagan FL, Mortimer JE,Katzenellenbogen lA, Welch MJ, Siegel BA.Positron emission tomographic assessment of"metabolic flare" to predict response of metastaticbreast cancer to anti-estrogen therapy. Eur J NuclMed 1999, 26; 51-6.
- Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K,Katzenellenbogen JA, Welch MJ. Metabolic flare:indicator of hormone responsiveness in advancedbreast cancer. J Clin Oneol 2001;19:2797-803.
- Wahl RL, Zasadny K, Helvie M, Hutchins GD,Weber B, Cody R. Metabolic monitoring of breastcancer chemoradiotherapy using positron emissiontomography: initail evaluation. J Clin Oneol1993,11,2101-11.
- Jansson T, Westlin JE, Ahlstrom H, Lilja A,Langstrom B, Bergh J. Positron emissiontomography studies in patients with locallyadvanced and/or metastatic breast cancer: a methodfor early therapy evaluation? J Clin Oneol1995;13:1470-7.
- Findly M, Young H, Cunning D, et al. Noninvasivemonitoring of tumor metabolism usingfluorodeoxyglucose and positron emissiontomography in colorectal cancer liver metastasis;correlation with tumor response to fluorouracil. JClin Oneol 1996; 14: 700-8.
- Hautzel H, Muller-Gartner HW, Early changes in fluorine-18-FDG uptake during radiotherapy J Nucl Med 1997;38:1384-6.
- Wiedmann E, Baican B, Hertel A, Baum RP, ChowKU, Knupp B, et al: Positron emissiontomography(PET) for stagng and evaluatiion ofresponse to treatment in patients with Hodgkin'sdisease. Leuk Lymphoma 1999;34:545-51.
- Zinzani PL, Magagnoli M, Chierichetti F,Zompatori M, Garraffa G, Bendandi M, et al. Therole of positron emission tomography (PET) in themanagement of lymphoma patients. Ann Oneol1999;10: 1181-4.
- Cermerius U, Fabry U, Kroll U, Zinmy M,Neuerburg J, Osieka R, et al. Clinical value ofFDG-PET for therapy monitoring of malignantlymphoma-results of retrospective study in 72patients. Nuklearmedizin 1999;38;24-30.
- Spaepen K, Stroobants S, Dupont P, VanSteenweghen S, Thomas J, Vandenberghe P, et al.Prognostic value of positron emission tomography(PET) with fluorine-18 fluorodeoxyglucose(C8F]FDG) after first-line chemotherapy in nonHodgkin'slymphoma: is C8F]FDG-PET a validalternative to conventional diagnostic methods? JClin Oneol 2001;19:414-9.
- De Santis M, Bokemeyer C, Becherer A, Stoiber F,Oechsle K, Kletter K, et al. Predictive impact of2-18fluoro-2-deoxy-D-glucose positron emissiontomography for residual postchemotherapy massesin patients with bulky seminoma. J Clin Oneol2001;19:3740-4.
- Brucher BL, Weber W, Bauer M, Fink U, Avril N,Stein HJ, et al. Neoadjuvant therapy of esophagealsquamous cell carcinoma: response evaluation bypositron emission tomography. Ann Surg 2001;233:300-9.
- Vansteekiste JF, Stroobants SG, Dupont PJ, DeLeyn PR, Verbeken EK, Deneffe GJ, et al.Prognostic importance of the standardized uptakevalue on 18F-fluoro-2-deoxy-glucose-positron emissiontomography scan in non-small-cell lung cancer; ananalysis of 125 cases. J Clin Oneol 1999; 7:3201-6.
- Ryu JS, Choi NC, Fischman AJ, lynch TJ, MathisenDJ; FDG-PET instaging and restaging non-smallcell lung cancer after neoajuvant chemoradiotherapy:correlation with histopathology. Lung Cancer 2002,35;179-87.
- van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE,Molenaar WM, Paans AM, et al. FDG-PET toevaluate responses to hyperthermic isolated limbperfusion for locally advanced soft tissue sarcoma.J Nucl Med 1996;37: 984-90.
- Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M,Yang DJ, et al. Evaluation of preoperativechemotherapy using PET with fluorine18-fluorodeoxyglucose in breast cancer. J Nucl Med1996; 37:931-8.
- Burcombe RJ, Makris A, Pittam M, Lowe J,Emmott J, Wong WL. Evaluation of good clinicalreponse to neoadjuvant chemotherapy in primarybreast cancer using [18F]-fluorodeoxyglucosepositron emission tomograpy. Eur J Cancer,2002;38:375-9.
- lchiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to cancer therapy using fluorine-18fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32:1655-60.
- Harberkorn U, Strauss LG, Dimitrakopoulou A, etal. PET studies of fluorodeoxy glucose metabolismin patients with recurrent colorectal tumors receivingradiotherapy. J Nucl Med 1991;32: 1485-90.
- Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF,Postmus PE, Teule GJJ, et al. Monitoring responseto therapy in cancer using [18F]-2-fluoro-2-deoxyD-glucose and positron emission tomography: anoverview of different analytical methods. Eur JNucl Med 2000;27:731-43.
- Stokkel MP, Draisma A, Pauwels EK. Positronemission tomography with 2-[18F]-fluoro-2-deoxyD-glucose in oncology. Part IlIb: Therapy responsemonitoring in colorectal and lung tumours, head andneck cancer, hepatocellular carcinoma and sarcoma.J Cancer Res Clin Oncol 2001;127:278-85.
- Kenneth R. Zasadny, richard L. Wahl. Standardizeduptake values of normal tissues at PET with2- [FI uorine-18] -FI uoro-2-deoxy- D- gl ucose:Variations with body weight and a method forcorrection. Radiology 1993;189-847-50.
- Keyes JW. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
- Weber WA, Schwaiger M, Avril N. Quantitativeassessment of tumor metabolism using FDG-PETimaging. Nucl Med Bioi 2000;27:683-7.
- Yao WJ, Hoh C. Quantitation of tumor glucosemetabolism with FDG and PET. Ann Nucl Med1995;8:104-14.
- Young H, Baum R, Cremerius U, Herholz K,Hoekstra 0, Lammertsma AA, et al. Measurementof clinical and subclinical tumour response using[18F]-fluorodeoxyglucose and positron emissiontomography: Review and 1999 EORTCrecommendations. Eur J Cancer 1999;35:1773-82.
- Eckelman WC, Tatum JL, Kurdziel KA, Croft BY.Quantitative analysis of tumor biochemisty usingPET and SPECT. Nucl Med Bioi 2000;27:633-5.
- van der Hiel B, Pauwels EK, Stokkel MP. Positronemission tomography with 2-[18F]-fluoro-2-deoxyD-glucose in oncology. Part lIla: Therapy responsemonitoring in breast cancer, Iymphma and gliomas.J Cancer Res Clin Oncol 2001;127:269-77.
- Mankoff DA, Bellon JR. Positron-emissiontomographic imaging of cancer: glucose metabolismand beyond. Semin Radiat Oncol 2001;11:16-27.